Provided by Tiger Trade Technology Pte. Ltd.

Relay Therapeutics

18.66
-0.4500-2.35%
Pre-market: 18.790.1300+0.70%08:12 EDT
Volume:6.06M
Turnover:114.54M
Market Cap:4.09B
PE:-11.92
High:19.19
Open:18.76
Low:18.54
Close:19.11
52wk High:21.27
52wk Low:3.89
Shares:219.14M
Float Shares:145.00M
Volume Ratio:2.24
T/O Rate:4.18%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5651
EPS(LYR):-1.6113
ROE:-36.77%
ROA:-22.88%
PB:4.59
PE(LYR):-11.58

Loading ...

Relay Therapeutics Q2 Revenue Misses Estimates on Higher R&D Expenses; Net Loss Widens

Reuters
·
Aug 07

Relay Therapeutics Q2 EPS $(0.41) Misses $(0.39) Estimate, Sales $350.000K Miss $872.727K Estimate

Benzinga Earnings
·
Aug 07

Relay Therapeutics Q2 Net Income USD -83.707 Million Vs. IBES Estimate USD -74.2 Million

Reuters
·
Aug 07

Relay Therapeutics Q2 Operating Expenses USD 91.174 Million

THOMSON REUTERS
·
Aug 07

Relay Therapeutics Q2 EPS USD -0.41

THOMSON REUTERS
·
Aug 07

Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates

GlobeNewswire
·
Aug 07

Is Relay Therapeutics (RLAY) Turning Zovegalisib Updates Into a Credibility Test for Its Pipeline Strategy?

Simply Wall St.
·
Jul 31

Relay Therapeutics to Report Q2 Results After Markets Close

Reuters
·
Jul 31

Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026

GlobeNewswire
·
Jul 31

Relay Therapeutics is Maintained at Buy by Goldman Sachs

Dow Jones
·
Jul 21

Relay Therapeutics Inc : Canaccord Genuity Initiates Coverage with Buy Rating; Price Target $29

THOMSON REUTERS
·
Jul 16

Canaccord Genuity Initiates Relay Therapeutics at Buy With $29 Price Target

MT Newswires Live
·
Jul 16

Relay Therapeutics Initiated at Buy by Canaccord Genuity

Dow Jones
·
Jul 16

Relay Therapeutics initiated with a Buy at Canaccord

TIPRANKS
·
Jul 16

Relay Therapeutics CFO Thomas Catinazzo Sells 17,717 Common Shares Worth $331,104.73

Reuters
·
Jul 09

Why Relay Therapeutics (RLAY) Is Up 5.5% After Broad Russell Growth Index Inclusion And What's Next

Simply Wall St.
·
Jul 08

Relay Therapeutics Initiated at Overweight by JP Morgan

Dow Jones
·
Jul 08

U.S. Research Roundup- Alliant Energy, Prog Holdings, Travelers

Reuters
·
Jul 08

Relay Therapeutics Inc : JP Morgan Initiates Coverage with Overweight Rating; Target Price $28

THOMSON REUTERS
·
Jul 08

Relay Therapeutics Chief Corporate Development Officer Peter Rahmer Sells 50,000 Shares for $954,500

Reuters
·
Jul 03